Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Double-blind, Randomized, Placebo-controlled, Multi-center Trial to Evaluate the Efficacy and Safety of AR1001 Over 52 Weeks in Participants With Early Alzheimer's Disease (Polaris-AD)

NCT05531526 is registered in ClinicalTrials.gov with AriBio Co., Ltd. as lead sponsor.

NCT NCT05531526
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05531526 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Double-blind, Randomized, Placebo-controlled, Multi-center Trial to Evaluate the Efficacy and Safety of AR1001 Over 52 Weeks in Participants With Early Alzheimer's Disease (Polaris-AD)
Lead sponsor
AriBio Co., Ltd.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
December 23, 2022
Completion date
October 31, 2027
Enrollment
1,535 (actual)
Sites
198

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease